# Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder

> **NCT02046564** · PHASE3 · COMPLETED · sponsor: **Otsuka Pharmaceutical Co., Ltd.** · enrollment: 412 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** ASC-01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02046564
- **Lead sponsor:** Otsuka Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02
- **Primary completion:** 2016-09
- **Final completion:** 2016-09
- **Target enrollment:** 412 (ACTUAL)
- **Last updated:** 2018-05-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02046564

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02046564, "Assess the Efficacy and Safety of ASC-01 in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02046564. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*